EP3934640A4 - Zusammensetzung mit einer monoacetyldiacylglycerolverbindung zur behandlung von fettleberkrankheit - Google Patents

Zusammensetzung mit einer monoacetyldiacylglycerolverbindung zur behandlung von fettleberkrankheit Download PDF

Info

Publication number
EP3934640A4
EP3934640A4 EP20766948.2A EP20766948A EP3934640A4 EP 3934640 A4 EP3934640 A4 EP 3934640A4 EP 20766948 A EP20766948 A EP 20766948A EP 3934640 A4 EP3934640 A4 EP 3934640A4
Authority
EP
European Patent Office
Prior art keywords
composition
liver disease
fatty liver
treating fatty
monoacetyldiacylglycerol compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20766948.2A
Other languages
English (en)
French (fr)
Other versions
EP3934640A1 (de
Inventor
Ki Young SOHN
Jae Wha Kim
Sun Young Yoon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzychem Lifesciences Corp
Original Assignee
Enzychem Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190086967A external-priority patent/KR102218545B1/ko
Application filed by Enzychem Lifesciences Corp filed Critical Enzychem Lifesciences Corp
Priority claimed from PCT/IB2020/051990 external-priority patent/WO2020178803A1/en
Publication of EP3934640A1 publication Critical patent/EP3934640A1/de
Publication of EP3934640A4 publication Critical patent/EP3934640A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP20766948.2A 2019-03-07 2020-03-06 Zusammensetzung mit einer monoacetyldiacylglycerolverbindung zur behandlung von fettleberkrankheit Withdrawn EP3934640A4 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20190026326 2019-03-07
KR1020190086967A KR102218545B1 (ko) 2019-03-07 2019-07-18 모노아세틸디아실글리세롤 화합물을 유효성분으로 함유하는 지방간 질환 치료용 조성물
US201962908392P 2019-09-30 2019-09-30
PCT/IB2020/051990 WO2020178803A1 (en) 2019-03-07 2020-03-06 Composition comprising monoacetyldiacylglycerol compound for treating fatty liver disease

Publications (2)

Publication Number Publication Date
EP3934640A1 EP3934640A1 (de) 2022-01-12
EP3934640A4 true EP3934640A4 (de) 2022-12-07

Family

ID=76446703

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20766948.2A Withdrawn EP3934640A4 (de) 2019-03-07 2020-03-06 Zusammensetzung mit einer monoacetyldiacylglycerolverbindung zur behandlung von fettleberkrankheit

Country Status (4)

Country Link
EP (1) EP3934640A4 (de)
JP (1) JP2022523464A (de)
CN (1) CN113194940A (de)
AU (1) AU2020231261A1 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3037090A1 (de) * 2013-08-19 2016-06-29 Enzychem Lifesciences Corporation Zusammensetzung mit einer monoacetyldiglyceridverbindung als wirkstoff zur prävention oder behandlung von rheumatischer arthritis
WO2018070854A2 (ko) * 2016-10-13 2018-04-19 주식회사 엔지켐생명과학 모노아세틸디아실글리세롤 화합물을 함유하는 간염의 예방 또는 치료용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014309570B2 (en) * 2013-08-19 2017-04-20 Enzychem Lifesciences Corporation Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating asthma
WO2018046876A1 (en) * 2016-09-06 2018-03-15 The University Of Birmingham Treatment of chronic inflammatory disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3037090A1 (de) * 2013-08-19 2016-06-29 Enzychem Lifesciences Corporation Zusammensetzung mit einer monoacetyldiglyceridverbindung als wirkstoff zur prävention oder behandlung von rheumatischer arthritis
WO2018070854A2 (ko) * 2016-10-13 2018-04-19 주식회사 엔지켐생명과학 모노아세틸디아실글리세롤 화합물을 함유하는 간염의 예방 또는 치료용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Abstracts 1 to 258", HEPATOLOGY, JOHN WILEY & SONS, INC, US, vol. 44, 25 September 2006 (2006-09-25), pages 188A - 286A, XP071560995, ISSN: 0270-9139, DOI: 10.1002/HEP.21395 *
KIM MYUNG-HWAN ET AL: "EC-18, A Novel Immune Resolution Accelerator, Improves Nash and Liver Fibrosis", HEPATOLOGY; 70TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVER-DISEASES (AASLD) / LIVER MEETING; BOSTON, MA, USA; NOVEMBER 08 -12, 2019, JOHN WILEY & SONS, INC, US, vol. 70, no. Suppl. 1, 1 October 2019 (2019-10-01), pages 1258A - 1259A, XP009540056, ISSN: 0270-9139 *
See also references of WO2020178803A1 *

Also Published As

Publication number Publication date
EP3934640A1 (de) 2022-01-12
AU2020231261A1 (en) 2021-06-24
CN113194940A (zh) 2021-07-30
JP2022523464A (ja) 2022-04-25

Similar Documents

Publication Publication Date Title
EP3934652A4 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von krankheiten
EP3890725A4 (de) Zusammensetzungen zur behandlung von hauterkrankungen
EP3915583A4 (de) Kombinierte pharmazeutische zusammensetzung zur tumorbehandlung
EP3838937A4 (de) Fotopolymerzusammensetzung
EP3685840A4 (de) Pharmazeutische verbundzusammensetzung zur behandlung entzündlicher hauterkrankungen
EP3852753A4 (de) Behandlung von nichtalkoholischer fettlebererkrankung
EP4013853A4 (de) Verbesserte verfahren zur herstellung von organoidzusammensetzungen
EP3824296A4 (de) Lebererkrankung
EP4045094A4 (de) Zusammensetzungen und verfahren zur behandlung von lebererkrankung
EP3653219A4 (de) Zusammensetzung zur behandlung von fettleber
EP3933030A4 (de) Zusammensetzung zur vorbeugung, linderung oder behandlung von fettleibigkeit oder lebererkrankungen mit weissella hellenica wikim0103
EP3760055A4 (de) Zusammensetzung zur hemmung der fettansammlung
EP3970745A4 (de) Pharmazeutische zusammensetzung zur tumorbehandlung
EP3866852A4 (de) Zusammensetzungen und verfahren zur behandlung von lebererkranungen
EP3974026A4 (de) Zusammensetzung zur verbesserung der leberfunktionen
EP3781158A4 (de) Zusammensetzungen zur behandlung von nicht-alkoholischer fettlebererkrankung und nicht-alkoholischer steatohepatitis
EP4031130A4 (de) Verfahren zur behandlung von soliden tumoren
EP3773539A4 (de) Zusammensetzungen zur hautbehandlung
EP3911329A4 (de) Zusammensetzung zur prävention oder behandlung von stoffwechsellebererkrankungen
EP3927375A4 (de) Zusammensetzungen zur behandlung von krankheiten
EP3958892A4 (de) Verfahren zur behandlung von leberkrankheit
EP3760293A4 (de) Zusammensetzung zur beseitigung einer schwefelhaltigen verbindung
EP3766363A4 (de) Zusammensetzung zur verbesserung von hautleiden
EP3934640A4 (de) Zusammensetzung mit einer monoacetyldiacylglycerolverbindung zur behandlung von fettleberkrankheit
EP4154880A4 (de) Arzneimittel zur behandlung von fettlebererkrankungen

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210601

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031230000

Ipc: A61K0031231000

A4 Supplementary search report drawn up and despatched

Effective date: 20221107

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 1/16 20060101ALI20221031BHEP

Ipc: A23L 33/115 20160101ALI20221031BHEP

Ipc: A61K 45/06 20060101ALI20221031BHEP

Ipc: A61K 31/231 20060101AFI20221031BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230606